MediWound Ltd.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About MediWound
Medicinal Chemicals & Botanical Products, SIC 2833
MediWound Ltd. is a biopharmaceutical company that develops and commercializes therapeutics for burn care and wound management. Its primary products and pipeline product candidates include NexoBrid and EscharEx. The company serves healthcare providers and institutional partners, collaborating with government organizations such as the United States Biomedical Advanced Research and Development Authority, commercial pharmaceutical partners including Vericel and Teva, and regional burn centers and medical units.
The company is headquartered in Yavne, Israel, where it is also incorporated. Its operational scale and geographic presence span multiple countries, including the United States, Israel, and several European nations such as Germany, Italy, and Spain. MediWound operates dedicated manufacturing facilities to produce intermediate drug substances and finished goods for its research programs, clinical trials, and international commercial supply.
Summary of the business section of MediWound's latest annual report, written by StockData.
Company profile
Company
- Legal name
- MediWound Ltd.
- Headquarters
- Yavne, L3
- Address
- 42 Hayarkon Street 8122745
- Phone
- 972779714100
- Employees
- 35, Dec 31, 2025
- Industry
- Medicinal Chemicals & Botanical Products
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- Somekh Chaikin, Tel Aviv, Israel
Stock & identifiers
- Ticker
- MDWD
- Exchange
- Nasdaq
- IPO date
- Mar 21, 2014
- Shares outstanding
- 13M, Dec 31, 2025
- Filer category
- Accelerated filer
- Stock splits
- 1-for-7 reverse, Mar 16, 2023; 1-for-7 reverse, Dec 20, 2022
- SEC CIK
- 1593984
- CUSIP
- M68830112
- ISIN
- USM688301128
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Shmuel Hess | COO & Chief Commercial Officer | 0 |
| Ety Klinger | Chief Medical Officer | 1,500 |
| Ofer Gonen | Chief Executive Officer | 8,500 |
| Yaron Meyer | EVP, GC & Corp. Secretary | 2,357 |
| Yaakov Aya Ben | VP Clinical & Reg. Affairs | 125 |
| Kalfon Hana Luxenburg | Chief Financial Officer | 3,000 |
| Samuel Rubinstein | Director | 750 |
| Nachum Shamir | Director | 55,815 |
| David Morton Fox | Director | 22,283 |
| Vickie Rae Driver | Director | 750 |
| Stephen T. Wills | Director | 750 |
Employees
Headcount reported in annual reports
“Our research and development team is located at our facilities in Yavne and Gan-Rave, Israel, and consists of 35 employees as of December”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 21, 2014 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 12, 2014 | Listing | Registration of securities on an exchange (Form 8-A) |